• News
  • SAN DIEGO
  • BioTech

Roche to buy US biotech firm InterMune for $8.3B

Swiss pharmaceutical company Roche said Sunday it has reached an $8.3 billion deal to buy InterMune Inc., a California-based developer of treatments for lung diseases.

To continue reading, subscribe now
or
log in to your account
User Response
0 UserComments
Subscribe Today!